Spots Global Cancer Trial Database for Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
Official Title: Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study
Study ID: NCT00933517
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Centre Jean Perrin, Clermont-Ferrand, , France
Pole Santé République, Clermont-Ferrand, , France
Centre Georges François Leclerc, Dijon, , France
Centre Oscar Lambret, Lille, , France
CHU Dupuytren, Limoges, , France
Centre Léon Bérard, Lyon, , France
Centre Hospitalier, Montluçon, , France
Hôpital Tenon, Paris, , France
Institut Jean Godinot, Reims, , France
Institut de Cancérologie de la Loire, Saint Priest en Jarez, , France
Centre Paul Strauss, Strasbourg, , France
Centre Alexis Vautrin, Vandoeuvre les Nancy, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
